CG Oncology (NASDAQ:CGON) Trading Up 4.6%

CG Oncology, Inc. stock price (NASDAQ:CGON – Get Free Report ) rose 4.6% on Monday. The stock traded as high as $36.44 and last traded at $36.39. About 125,690 shares traded hands during mid-day trading, down 80% from the average daily volume of 635,088 shares. Shares previously closed at $34.80.

The Wall Street analyst weighs in

Several equities research analysts have recently issued reports on CGON shares. Bank of America began coverage on CG Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $65.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Tuesday. Roth Mkm initiated coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. Finally, Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. CG Oncology presently has a consensus rating of “Buy” and an average price target of $64.17, based on data from MarketBeat.

Read our latest research report on CG Oncology

CG Oncology price performance

The company has a 50-day simple moving average of $35.04 and a 200-day simple moving average of $35.36.

CG Oncology (NASDAQ:CGON – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million during the quarter. As a group, equities analysts expect CG Oncology, Inc. to record -1.47 EPS for the current year.

Indoor activity

In other news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Institutional inputs and outputs

Several hedge funds have recently made changes to their positions in CGON. Ameritas Investment Partners Inc. bought a new stake in CG Oncology in the first quarter worth $102,000. California State Teachers Retirement System purchased a new position in CG Oncology during the first quarter valued at about $103,000. Profund Advisors LLC bought a new position in CG Oncology in the second quarter valued at approximately $300,000. BNP Paribas Financial Markets bought a new stake in shares of CG Oncology in the 1st quarter valued at about $492,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of CG Oncology during the first quarter valued at about $806,000. 26.56% of the shares are held by hedge funds and other institutional investors.

CG Oncology Company Profile

(Get a free report)

CG Oncology, Inc, an oncolytic immunotherapy company, is focused on developing and commercializing bladder-sparing therapies for patients with bladder cancer. The company is developing BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive patients with muscle-invasive bladder cancer (NMIBC); CORE-001 to treat cretostimogen in combination with pembrolizumab in BCG-unresponsive high-risk NMIBC patients; and CORE-002 for the treatment of cretostimogen in combination with the checkpoint inhibitor nivolumab in patients with muscle-invasive bladder cancer.

Recommended articles

Get news and reviews for CG Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CG Oncology and related companies with MarketBeat.com ‘s FREE daily email newsletter.